News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Insys Therapeutics (INSY) Granted Orphan Drug Status for Cannabidiol for Brain Tumors


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is a big step forward for development of this line of treatment



Website: http://www.streetinsider.com/Corporate+News/Insys+Therapeutics+(INSY)+Granted+Orphan+Drug+Status+for+Cannabidiol+for+Brain+Tumors/9778750.html

Posted on: 08/25/2014

Insys Therapeutics (INSY) Granted Orphan Drug Status for Cannabidiol for Brain Tumors
 
Insys Therapeutics (NASDAQ: INSY) announced the FDA has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in humans.
 
"We are pleased to have received orphan drug designation for this aggressive and often incurable form of brain cancer. We look forward to advancing development of this product and offering a potential efficacious treatment for patients," said Michael L. Babich, President and Chief Executive Officer.
 
In addition to receiving ODD, Insys has recently entered into an exclusive licensing agreement with California Pacific Medical Center on behalf of its Research Institute (CPMCRI) based in San Francisco to license CPMCRI's patent rights related to the usage of cannabinoids for the treatment of GBM.

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740